Soligenix contacted OCF and asked permission to post and share their clinical study; see the notice below. If there are any new patients or patients in treatment, that would like to try to reduce their mucositis symptoms and learn more about this study, please contact Dr. Richard Straube, Chief Medical Officer - Soligenix at (609) 538-8200, extension 30.

IMPORTANT NOTICE: A clinical study to assess the ability of an innovative investigational drug to prevent the development of severe oral mucositis in patients receiving chemoradiation for the treatment of their non-metastatic head and neck cancer is currently enrolling patients at a select group of ~20 medical centers across the United States. This study is being conducted by Soligenix Inc. who is studying the potential impact its investigational drug, known as SGX942, may have in preventing and reducing the severity of this common, devastating side effect of the cancer therapy. There are currently no FDA approved drugs for oral mucositis in head and neck cancer patients. To learn more about the study, please contact Dr. Richard Straube, Chief Medical Officer - Soligenix at (609) 538-8200, extension 30.




ADMIN NOTE**** For any general questions, please PM Christine. ****